commercialization agreement
Personalis believes the move will get its minimal residual disease test into the hands of doctors more quickly while it continues to validate additional indications.
In Brief This Week: Thermo Fisher Scientific, Quest Diagnostics, MDxHealth, Renalytix, More
News items for the week of Nov. 13, 2023
Boditech Med, SphingoTec Ink Commercialization Deal for Kidney Injury Test
The firms will market a point-of-care test that incorporates SphingoTec's kidney function biomarker and is designed for use on Boditech Med's AFIAS instruments.
Mainz Biomed, Fugene Genetics Partner on Colorectal Cancer Test Launch in Israel
The deal is one of several struck this year by Mainz Biomed for the marketing of its stool sample-based ColoAlert molecular test for colorectal cancer.
Mainz Biomed Inks Commercialization Deals for Colorectal Cancer Test in UK, Spain
The test combines analysis of DNA, mRNA, and fecal immunohistochemistry to identify cancer in asymptomatic individuals from a stool sample.